Roche's $1.5 billion acquisition of Poseida (PSTX.US) is expected to complete the transaction in the first quarter of next year

The Zhitong Finance App learned that Poseida Therapeutics (PSTX.US), a leading company in the field of clinical-stage allogeneic cell therapy and gene drugs, announced that it will be acquired by Roche Holdings for a total equity value of about 1.5 billion US dollars. The acquisition includes $9.00 in cash per share, with additional non-tradable contingent value rights (CVR). Shareholders can expect to receive an additional cash payment of up to $4.00 per share after reaching certain milestones. The entire transaction is expected to be successfully completed in the first quarter of 2025. Poseida will continue to advance the development of its non-viral CAR-T therapies and genetic drugs as part of Roche Pharmaceuticals division.

Since 2022, Poseida and Roche have collaborated to develop ready-to-use Car-T cell therapy for patients with hematologic malignancies. The acquisition not only marks Poseida's formal entry into the Roche Group, but also indicates that both parties will make deeper progress in the field of allogeneic cell therapy.

Levi Garraway, Roche's Chief Medical Officer, said: “Building on our existing foundation of successful collaboration with Poseida, this acquisition will undoubtedly drive us to further breakthroughs in allogeneic cell therapy.”

Dr. Kristin Yarema, President and CEO of Poseida, is also looking forward to this collaboration: “We are excited to further deepen our collaboration with Roche to advance our product line and future projects. Roche's global strength in late-stage development and commercialization will undoubtedly help allo CAR-T's transformative potential benefit patients around the world.”

As of press release, Poseida rose more than 222% to $9.22 in the premarket.